Hematology

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

By Jared Kaltwasser

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

By Mary Caffrey
Caspian Oliai, MD, MS

April 11th 2025

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

By Jared Kaltwasser

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

By Jared Kaltwasser

April 8th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

By Kyle Munz
Ajai Chari, MD

April 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

Diabetes, Cancer Interviews Among Most-Watched Videos of 2018

December 20th 2018

Diabetes, Cancer Interviews Among Most-Watched Videos of 2018

Laura Joszt, MA

Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.

NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward

December 19th 2018

NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward

Jaime Rosenberg

During the 60th American Society of Hematology Annual Meeting & Exposition held December 1-4 in San Diego, California, Norman Sharpless, MD, director, National Cancer Institute (NCI), brought attention to several advances made in hematologic malignancies over the past year and highlighted 4 areas of focus going forward.

Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL

December 13th 2018

Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL

David Bai, PharmD

Ibrutinib-containing regimens have similar overall survival rates but significantly higher progression-free survival (PFS) rates at 2 years compared with bendamustine plus rituximab.

Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation

December 12th 2018

Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation

Jaime Rosenberg

Following failure with ruxolitinib, there are limited treatment options available and among these patients who fail on the treatment, prognosis is unfavorable, particularly among those who started ruxolitinib with advanced stage disease, according to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition.

ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma

December 8th 2018

ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma

David Bai, PharmD

ELOQUENT-3 trial results found that adding elotuzumab to pomalidomide and dexamethasone improved progression-free survival (PFS) and overall response rate in patients with multiple myeloma that had relapsed from or were refractory to (R/R) lenalidomide and a proteasome inhibitor.

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis

December 7th 2018

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis

Jaime Rosenberg

According to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition, held December 1-4 in San Diego, California, a World Health Organization–defined diagnosis of primary myelofibrosis may help better identify patients who may need strict monitoring during treatment with ruxolitinib.

$FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation$

December 3rd 2018

FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation

Laura Joszt, MA

Once-daily gilteritinib pills have been approved to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Approximately 25% to 30% of patients with AML have this mutation, which is associated with an aggressive form of the disease and carries a higher risk of relapse.

Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse

December 1st 2018

Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse

David Bai, PharmD

In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation

FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML

November 27th 2018

FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML

Laura Joszt, MA

FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.

November 27th 2018

Research to Look Out for at ASH 2018

Jaime Rosenberg

From December 1-4, hematology professionals from across the globe will convene in San Diego, California for the American Society of Hematology annual meeting to present and discuss their research and latest developments in malignant and non-malignant hematology. Here’s what to look out for during the meeting.

AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B

November 23rd 2018

AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B

David Bai, PharmD

AMT-061, an AAV5 vector containing factor IX (FIX)-Padua variant, has been shown to increase FIX activity to threshold FIX levels sufficient to significantly reduce the risk of bleeding events without the risk of adverse immune reactions.

Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease

November 20th 2018

Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease

Laura Joszt, MA

A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.

Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy

November 17th 2018

Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy

Since chimeric antigen receptor (CAR) T-cell therapy is still in early development there are benefits and risks that eligible patients will have to weigh, including the durable response against the limited amount of data and toxic side effects, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.

FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma

November 17th 2018

FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma

Allison Inserro

The FDA announced Friday it expanded the approved use of brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma, using a new review process designed to increase efficiency.

CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma

November 15th 2018

CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma

David Bai, PharmD

When used in combination with rituximab, Hu5F9-G4 (5F9), a humanized monoclonal anti-CD47 antibody, promotes durable objective and complete response rates in lymphoma while also having minimal adverse events (AE), according to a phase 1b study published in New England Journal of Medicine.

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

November 13th 2018

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

Laura Joszt, MA

Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.

$Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma$

November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA

Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.

ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens

November 7th 2018

ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens

David Bai, PharmD

Children and adolescents with acute lymphoblastic leukemia (ALL) face an increased risk of obesity and growth impairment from the disease and during ALL treatment, regardless of exposure to cranial irradiation, according to a recent study.

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

November 2nd 2018

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

Laura Joszt, MA

While survival from leukemia improved among adults from 1995 to 2009, and the survival gap between sexes decreased, the racial gap did not, according to new research published in Cancer.

Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma

October 31st 2018

Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma

The analysis comes amid a debate set off when CVS Caremark announced that it would allow self-funded insurers to exclude drugs that entered the market above $100,000 per quality-adjusted life year.

The Evolution of CLL Testing and Treatment Over the Past Decade

October 30th 2018

The Evolution of CLL Testing and Treatment Over the Past Decade

Laura Joszt, MA

In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.

October 25th 2018

Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS

A life-saving therapy is challenging to administer and poses financial risks for patients and institutions alike. Speakers at the Academy of Managed Care Pharmacy Nexus 2018 address some approaches to paying for it while CMS develops long-term policies.

October 24th 2018

Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.

October 24th 2018

Study Summary: Response and Progression-Free Survival at 18 Months With Lenalidomide and Dexamethasone

Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.

October 24th 2018

Study Summary: Once-Weekly Versus Twice-Weekly Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma: ARROW Interim Analysis

Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.

October 24th 2018

Study Summary: Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma

Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide, dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018, 8(8):70. doi: 10.1038/s41408-018-0106-3.

One Gene Could Be Responsible for Acute Myeloid Leukemia

October 21st 2018

One Gene Could Be Responsible for Acute Myeloid Leukemia

Laura Joszt, MA

The EVI1 gene may be single-handedly at fault for acute myeloid leukemia, according to research published in Nature Communications.

October 18th 2018

Study Summary: Cardiovascular Safety Profile of Carfilzomib in Multiple Myeloma Clinical Trials

Chari A, Stewart AK, Russell SD, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood advances. 2018, 2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.

October 18th 2018

Study Summary: Carfilzomib + Dexamethasone Versus Bortezomib (SC or IV) + Dexamethasone in Relapsed or Refractory Multiple Myeloma (ENDEAVOR Secondary Analysis)

Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.

October 18th 2018

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma [published online April 4, 2018]. Leuk Lymphoma. 2018:1-7. doi: 10.1080/10428194.2018.1443337.

...

12 13 14 15 16 17 18 19 20

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions